Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

Table 1 Clinical and cytogenetic data of MM patients

N. Don	1	2	3	4	5	6	7	8	9
YOB	1966	1958	1954	1944	1961	1961	1962	1951	1949
% CD138	17.5	28.0	16.0	23.0	32.9	19.8	14.8	25.7	11.0
Gender	Male	Male	Male	Male	Female	Male	Male	Female	Male
SMM vs NDMM vs RRMM	NDMM	NDMM	SMM	NDMM	RRMM	NDMM	NDMM	NDMM	RRMM
Drug exposure	N/Ap	N/Ap	N/Ap	N/Ap	BTZ, THA, MEL, LEN	N/Ap	N/Ap	N/Ap	BTZ, THA, MEL, CFZ, LEN
Drug refractoriness	N/Ap	N/Ap	N/Ap	N/Ap	LEN	N/Ap	N/Ap	N/Ap	BTZ, THA
N. of prior lines	0	0	0	0	1	0	0	0	2
Disease isotype	IgG k	IgG l	IgA l	FLC k	FLC k	IgG l	IgG k	IgG k	IgG k
ISS at diagnosis	2	1	NP	N/A	2	1	3	1	2
Del(17p)	Neg	Neg	Neg	Neg	Pos	Neg	Neg	Pos	Pos
T(4;14)	Neg	Neg	Neg	Neg	Neg	Pos	Neg	Neg	N/A
T(14;16)	Neg	Neg	Neg	Neg	Neg	Neg	Neg	Neg	N/A
Gain/Amp(1q)	Neg	Neg	Neg	N/A	Pos	Pos	Neg	Pos	Neg
Del(1p)	Neg	Neg	Neg	N/A	Neg	Neg	Neg	Neg	Neg
T(11;14)	Neg	Neg	Pos	N/A	Pos	Neg	Neg	N/A	N/A
Del(13q)	Neg	Neg	Neg	N/A	Pos	Pos	Pos	N/A	Pos

YOB: Years of born; N/A: Not Available; N/Ap: Not Applicable; ISS: International Staging System; SMM: Smoldering MM; NDMM: New Diagnosed MM; RRMM: Relapse/refractory MM; BTZ: bortezomib; CFZ: carfilzomib; THA: Thalidomide; MEL: Melphalan; LEN: Lenalidomide

ISSN: 2162-3619